Sign Up to like & get recommendations! 0
Published in 2021 at "Chemistry and physics of lipids"
DOI: 10.1016/j.chemphyslip.2021.105081
Abstract: The aim of this research was to study the effect of marketed tablet (Crestor®) powder suspension (MTPS) and nanoparticle formulation of rosuvastatin calcium (RC) on the pharmacokinetic (PK) and pharmacodynamic (PD) parameters in hyperlipidemia rats.… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "European Journal of Pharmaceutics and Biopharmaceutics"
DOI: 10.1016/j.ejpb.2016.10.022
Abstract: &NA; The intent of this investigation was to improve pharmacokinetic (PK) and pharmacodynamic (PD) effects of Rosuvastatin calcium (RC) by solid lipid nanoparticles (SLNs). RC is anti‐hyperlipidemic drug with low oral bioavailability (20%) due to… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Tetrahedron Letters"
DOI: 10.1016/j.tetlet.2017.05.075
Abstract: Abstract During the process development for multistep synthesis of Rosuvastatin calcium several impurities were obtained along with the final Rosuvastatin calcium. Out of this; synthesis of impurity A (acetone adduct) a minor impurity of Rosuvastatin… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "New Journal of Chemistry"
DOI: 10.1039/c7nj01214d
Abstract: Restenosis caused by thrombopoiesis is one of the biggest hindrances to endovascular stent-grafts. Rapid endothelialization of the lumen of the stent is a promising approach to prevent thrombosis. A stent-graft covered with heparin and rosuvastatin… read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "Drug Development and Industrial Pharmacy"
DOI: 10.1080/03639045.2020.1810264
Abstract: Abstract Despite being the most effective hypolipidemic agent, poor physicochemical properties of Rosuvastatin calcium (RCa) remain challenging obstacles in the development of pharmaceutical dosage forms. Inclusion complexes (ICs) of RCa with cyclodextrin (CD) derivatives; methyl-beta-cyclodextrin… read more here.
Sign Up to like & get recommendations! 0
Published in 2022 at "Pharmaceutical Development and Technology"
DOI: 10.1080/10837450.2022.2073370
Abstract: Abstract Reliable and stable tablet formulations for rosuvastatin calcium (RSC) in four strengths: 5 mg, 10 mg, 20 mg, and 40 mg have been developed. Rosuvastatin is a cholesterol-lowering statin drug and is known to be unstable during storage.… read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "International Journal of Applied Pharmaceutics"
DOI: 10.22159/ijap.2020v12i5.38175
Abstract: Objective: The objective of the present study was to develop sustained release biodegradable polymeric nanoparticles of rosuvastatin calcium. Methods: Nanoparticles were prepared by modified ionotropic gelation method using 3² full factorial designs. From the preliminary… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Pharmaceuticals"
DOI: 10.3390/ph15040492
Abstract: Poor solubility is the major challenge involved in the formulation development of new chemical entities (NCEs), as more than 40% of NCEs are practically insoluble in water. Solid dispersion (SD) is a promising technology for… read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "Pharmaceuticals"
DOI: 10.3390/ph16020242
Abstract: Sprinkle formulations represent an interesting concept of medicinal products aimed at the steadily growing population of patients suffering from swallowing difficulties (dysphagia). In the present work, immediate-release sprinkle MUPS (multiple-unit pellet system) containing rosuvastatin calcium… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics11060275
Abstract: In situ forming nanovesicular systems (IFNs) were prepared and optimized to improve Rosuvastatin calcium (RC) oral bioavailability through increasing its solubility and dissolution rate. The IFN was composed of Tween® 80 (T80), cetyl alcohol (CA),… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics14081629
Abstract: Hyperlipidemia is still the leading cause of heart disease in patients with hypertension. The purpose of this study is to make rosuvastatin calcium (ROS) and atenolol (AT) bilayer tablets to treat coexisting dyslipidemia and hypertension… read more here.